Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will present an overview of the company’s business at the 28th Annual Piper Jaffray Healthcare Conference in New York.
The presentation is scheduled for 4:30pm ET on November 29, 2016, at the Lotte New York Palace in New York City.
A replay of each presentation will be available via the investors section of the company’s website at www.intersectENT.com. The webcast replays will be archived for approximately one month.
About Intersect ENT
Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL® and PROPEL® Mini, which have been clinically proven to improve surgical outcomes for chronic sinusitis patients undergoing sinus surgery. In addition, Intersect ENT is developing a pipeline of steroid releasing implants designed to provide ENT physicians with options to treat patients across the continuum of care for chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition that can lead to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.
For additional information on the company or the products including risks and benefits please visit www.intersectENT.com.
INTERSECT ENT® and PROPEL® are registered trademarks of Intersect ENT, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161115005556/en/Business Wire
Last updated on: 15/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.